About rapport therapeutics inc - RAPP
Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.
RAPP At a Glance
Rapport Therapeutics, Inc.
99 High Street
Boston, Massachusetts 02110
| Phone | 1-857-321-8020 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -78,307,000.00 | |
| Sector | Health Technology | Employees | 69 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
RAPP Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.125 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.197 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.004 |
RAPP Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,134,884.058 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
RAPP Liquidity
| Current Ratio | 35.337 |
| Quick Ratio | 35.337 |
| Cash Ratio | 34.833 |
RAPP Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -33.297 |
| Return on Equity | -35.086 |
| Return on Total Capital | -25.515 |
| Return on Invested Capital | -34.913 |
RAPP Capital Structure
| Total Debt to Total Equity | 0.483 |
| Total Debt to Total Capital | 0.481 |
| Total Debt to Total Assets | 0.469 |
| Long-Term Debt to Equity | 0.242 |
| Long-Term Debt to Total Capital | 0.241 |